Comparative Pharmacology
Head-to-head clinical analysis: DURANEST versus MEPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURANEST versus MEPIVACAINE HYDROCHLORIDE.
DURANEST vs MEPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Mepivacaine hydrochloride is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by binding to sodium channels in the neuronal cell membrane, thereby stabilizing the membrane and preventing depolarization.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
1-2% solution, 5-20 mL local infiltration or nerve block, maximum 400 mg per procedure.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours). In neonates and patients with hepatic dysfunction, half-life may be prolonged up to 8–10 hours.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Primarily hepatic metabolism via amidase enzymes; ~95% excreted as metabolites in bile and feces, <5% unchanged in urine.
Category C
Category C
Local Anesthetic
Local Anesthetic